CYP3A5 phenotype-genotype correlations in a British population

Area of Science:

• Pharmacogenomics
• Molecular Biology
• Genetics

Background:

• CYP3A5 is a key enzyme in drug metabolism.
• Accurate genotyping for CYP3A5 expression is crucial for personalized medicine.
• Previous methods for CYP3A5 genotyping were complex or less accessible.

Purpose of the Study:

• To develop a simple Polymerase Chain Reaction (PCR)-Restriction Fragment Length Polymorphism (RFLP) assay for hepatic CYP3A5 genotyping.
• To validate the assay's accuracy using DNA sequencing and liver expression data.
• To determine the frequency of CYP3A5 alleles in a British population.

Main Methods:

• Designed CYP3A5-specific primers, incorporating a RsaI site for the CYP3A5*3 allele.
• Utilized PCR and RsaI digestion, followed by electrophoresis to differentiate genotypes.
• Validated the assay with DNA sequencing and genotyped 100 individuals from North-east England and 22 human liver samples.

Main Results:

• The PCR-RFLP assay successfully differentiated CYP3A5 expressors (CYP3A5*1 allele) from non-expressors (CYP3A5*3 homozygotes).
• In the British population, 13% (95% CI 6%, 20%) were predicted to have significant hepatic CYP3A5 expression.
• The CYP3A5*1 allele frequency was 0.065 (95% CI 0.032, 0.097), consistent with previous reports.

Conclusions:

• A straightforward PCR-RFLP assay for CYP3A5*1/*3 allele detection has been established.
• The assay demonstrated a strong correlation between hepatic CYP3A5 expression and genotype in a British Caucasian liver bank.
• The findings support the utility of this assay for pharmacogenomic studies in diverse populations.